Kevin J. Appelbaum - Dec 2, 2021 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Mark Heinen, Attorney-in-Fact for Kevin J. Appelbaum
Stock symbol: BTTX
Transactions as of: Dec 2, 2021
Transactions value $: $6,633
Form type: 4
Date filed: 12/6/2021, 04:34 PM
Previous filing: Nov 1, 2021
Next filing: Dec 14, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTTX	Common Stock	Purchase	$3.42K	+500		$6.84^*	500	Dec 2, 2021	Direct
transaction	BTTX	Common Stock	Purchase	$3.21K	+500	+100%	$6.43^*	1K	Dec 3, 2021	Direct	F1
holding	BTTX	Common Stock						2.41M	Dec 2, 2021	By Trust	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.440 to $6.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2	These shares are owned directly by Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (the "Trust"), and indirectly by Mr. Appelbaum as trustee of the Trust. Mr. Appelbaum is an officer, director and ten percent owner of the Issuer.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.440 to $6.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

These shares are owned directly by Kevin Appelbaum, or his successor(s), as Trustee of the Kevin Appelbaum Revocable Trust under Revocable Trust Declaration dated May 16, 2020, as amended (the "Trust"), and indirectly by Mr. Appelbaum as trustee of the Trust. Mr. Appelbaum is an officer, director and ten percent owner of the Issuer.